Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

BACKGROUND: Elderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma activities and can be applied to treat DLBCL. This study aimed to evaluate efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mu-Chen, Fang, Ying, Wang, Li, Cheng, Shu, Fu, Di, He, Yang, Zhao, Yan, Wang, Chao-Fu, Jiang, Xu-Feng, Song, Qi, Xu, Peng-Peng, Zhao, Wei-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585299/
https://www.ncbi.nlm.nih.gov/pubmed/33097085
http://dx.doi.org/10.1186/s13148-020-00948-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585299/
https://www.ncbi.nlm.nih.gov/pubmed/33097085
http://dx.doi.org/10.1186/s13148-020-00948-9

Ejemplares similares